ADC Therapeutics SA (ADCT)
NYSE: ADCT
· 即時價格 · USD
1.17
+0.03 (2.63%)
收盤價： Aug 31, 2026, 3:59 PM
1.16
-0.85%
盤前: 4:03 AM
股價、關鍵數字和最新消息，都在這一頁。
ADC Therapeutics SA（ADCT）股價、分析與資料
2.63% (1D)
| 買價 | 0 |
| 市值 | 149M |
| 營收 (ttm) | 79.6M |
| 淨利（ttm） | -96.9M |
| 1.83 | |
| -0.6 | |
| n/a | |
| -0.79 | |
| P/B (ttm) | -0.65 |
| P/S (ttm) | 1.88 |
| 財報日期 | Nov 10, 2026 |
| 賣價 | 0 |
| 成交量 | 1,251,515 |
| 20 日平均成交量 | 2,036,961 |
| 開盤價 | 1.13 |
| 前收盤價 | 1.14 |
| 當日區間 | 1.12 - 1.19 |
| 52 週範圍 | 0.78 - 4.98 |
| 分析師 | n/a |
| 目標價 | 3 (156.41%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell l...
完整的公司簡介財務表現
ADC Therapeutics SA 在 2025 年的營收為 81.36M，較前一年的 70.84M 增加 14.85%。 淨利為 -142.62M，較前期減少 -9.64%。
財務報表財報驚奇
ADC Therapeutics SA 已於 Aug 13, 2026 公布季度財報：
- 營收為 $20.85M 低於預期 $0, 年增 -9.47% 下滑.
- 每股盈餘為 -0.11 超出預期 0.11, 年增 78.00% 成長.
第 1 頁，共 2 頁